{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "VIKING THERAPEUT.DL -,005", "longName": "Viking Therapeutics, Inc.", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 21.26, "averageDailyVolume3Month": 328, "averageDailyVolume10Day": 1034, "fiftyTwoWeekLowChange": 19.445002, "fiftyTwoWeekLowChangePercent": 10.1013, "fiftyTwoWeekRange": "1.925 - 21.8", "fiftyTwoWeekHighChange": -0.4299984, "fiftyTwoWeekHighChangePercent": -0.019724699, "fiftyTwoWeekLow": 1.925, "fiftyTwoWeekHigh": 21.8, "earningsTimestamp": 1682541000, "earningsTimestampStart": 1690315200, "earningsTimestampEnd": 1690833600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.87, "epsForward": -1.08, "epsCurrentYear": -0.81, "priceEpsCurrentYear": -26.382717, "sharesOutstanding": 99839400, "bookValue": 1.69, "fiftyDayAverage": 14.22374, "fiftyDayAverageChange": 7.146261, "fiftyDayAverageChangePercent": 0.50241786, "twoHundredDayAverage": 7.328025, "twoHundredDayAverageChange": 14.041976, "twoHundredDayAverageChangePercent": 1.9162021, "marketCap": 2160656640, "forwardPE": -19.787037, "priceToBook": 12.644971, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 1.7134726, "regularMarketPrice": 21.37, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1431324000000, "priceHint": 2, "regularMarketChange": 0.3600006, "regularMarketTime": 1683895179, "regularMarketDayHigh": 21.8, "regularMarketDayRange": "21.03 - 21.8", "regularMarketDayLow": 21.03, "regularMarketVolume": 1350, "regularMarketPreviousClose": 21.01, "bid": 20.25, "ask": 20.46, "bidSize": 2900, "askSize": 2800, "symbol": "1VT.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 56, "title": "Pres, CEO & Director", "yearBorn": 1966, "fiscalYear": 2021, "totalPay": {"raw": 872000, "fmt": "872k", "longFmt": "872,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1414261, "fmt": "1.41M", "longFmt": "1,414,261"}}, {"maxAge": 1, "name": "Mr. Gregory S. Zante", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2021, "totalPay": {"raw": 536000, "fmt": "536k", "longFmt": "536,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 57, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2021, "totalPay": {"raw": 543000, "fmt": "543k", "longFmt": "543,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 372305, "fmt": "372.31k", "longFmt": "372,305"}}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 57, "title": "VP of Fin. & Admin.", "yearBorn": 1965, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Sr. VP of Pharmaceutical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}